docetaxel anhydrous has been researched along with prostaglandin d2 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (prostaglandin d2) | Trials (prostaglandin d2) | Recent Studies (post-2010) (prostaglandin d2) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 3,454 | 78 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, A; Fulzele, SV; Ichite, N; Jackson, T; Shaik, MS; Singh, M | 1 |
1 other study(ies) available for docetaxel anhydrous and prostaglandin d2
| Article | Year |
|---|---|
15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Immunologic Factors; In Situ Nick-End Labeling; Lung Neoplasms; Mice; PPAR gamma; Prostaglandin D2; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transplantation, Heterologous | 2007 |